Biologic drugs have revolutionised many medical conditions. Like all medicines there is a role for therapeutic drug monitoring (TDM) with some agents in The utility of TDM biologic will be explored, covering methods detection as well the evidence that effective or otherwise.

Objective: Limited information exists on real-world use of anti-tumor necrosis factor-α (TNFα) biologic agents in ankylosing spondylitis (AS). This study evaluated the treatment patterns and costs of anti-TNFα biologic therapy and disease-modifying antirheumatic drugs (DMARDs) in patients with AS. Methods: MarketScan claim databases were used to identify anti-TNFα biologic treatment-naïve AS pa...

INTRODUCTION This study aimed to describe treatment changes (discontinuation, switching, and therapy add-on) following the initiation of biologic or nonbiologic oral disease-modifying antirheumatic drugs (DMARDs) in psoriatic arthritis (PsA) patients. METHODS Adult patients with ≥2 PsA diagnoses from physician office visits, initiated on a biologic or nonbiologic oral DMARD, were selected fro...

1. Distinguish between biologic DMARD use and nonbiologic DMARD use in the treatment of rheumatoid arthritis (RA). 2. Assess the differences between classes of biologic disease-modifying antirheumatic drug (DMARD) therapy. 3. Based on individual patient characteristics, construct a treatment and monitoring plan for a patient with RA and, when appropriate, include biologic DMARD therapy. 4. Just...

PURPOSE Despite American College of Rheumatology recommendations, appropriate and timely initiation of biologic therapies does not always occur. This study examined openness to and preference for attributes of biologic therapies among patients with rheumatoid arthritis (RA), differences in patients' and rheumatologists' perceptions, and discussions around biologic therapy initiation. PATIENTS...